1. bookVolume 8 (2015): Edition 1 (June 2015)
Détails du magazine
License
Format
Magazine
eISSN
1313-9053
Première parution
08 Sep 2014
Périodicité
2 fois par an
Langues
Anglais
Accès libre

Experimental Study On The Development Of Tolerance And Withdrawal Syndrome To Pentylenetetrazole-Induced Seizures In Rats Treated With Retigabine

Publié en ligne: 10 Dec 2015
Volume & Edition: Volume 8 (2015) - Edition 1 (June 2015)
Pages: 9 - 12
Reçu: 19 Oct 2014
Accepté: 18 May 2015
Détails du magazine
License
Format
Magazine
eISSN
1313-9053
Première parution
08 Sep 2014
Périodicité
2 fois par an
Langues
Anglais

1. Loscher W. Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia. 2006;47(8):1253-84.10.1111/j.1528-1167.2006.00607.xSearch in Google Scholar

2. Peychev L P. New experimental data in neuropharmacological characteristics of sodium valproate with repeated administration and after withdrawal [dissertation]. Plovdiv: Medicinski Universitet; 1991.Search in Google Scholar

3. European Medicines Agency [internet]. London (UK): Trobalt. International Nonproprietary Name: retigabine. Procedure No. EMEA/H/C/001245. c2011 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/- [cited 2014 Sep 05].Search in Google Scholar

4. Splinter MY. Ezogabine (Retigabine) and its role in the treatment of partial-onset seizures: a review. Clin Ther. 2012;34(9):1845-56.10.1016/j.clinthera.2012.07.009Search in Google Scholar

5. Jentsch TJ. Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci. 2000;1(1):21-30.10.1038/35036198Search in Google Scholar

6. Akdogan I, Yonguc NG. Experimental Epilepsy Models and Morphologic Alterations of Experimental Epilepsy Models in Brain and Hippocampus. In: Kaneez FS, editor. Underlying Mechanisms of Epilepsy. InTech; 2011. P. 269-82.10.5772/19928Search in Google Scholar

7. Rostock A, Tober C, Rundtelt C, Bartsch R, Engel J, Polymeropoulos EE, et al. D-23129: a new anticonvulsant with broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. 1996;23(3):211-23.10.1016/0920-1211(95)00101-8Search in Google Scholar

8. Sander SE, Lemm C, Lange N et al. Retigabine, a Kv7 (KCNQ) potassium channel opener, attenuates L-DOPA-induce dyskinesias in 6-OHDA-lesioned rats. Neuropharmacology. 2012;62(2):1052-61.10.1016/j.neuropharm.2011.10.01622079161Search in Google Scholar

9. Blackburn-Munro G, Dalby-Brown W, Mirza NR et al. Retigabine: Chemical Synthesis to Clinical Application. CNS Drug Rev. 2005,11(1):1-20.10.1111/j.1527-3458.2005.tb00033.x674176415867950Search in Google Scholar

10. Orhan G, Wuttke TV, Nies AT, Schwab M, Lerche H. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data. Expert Opin Pharmacother. 2012;13(12):1807-16.10.1517/14656566.2012.70627822783830Search in Google Scholar

11. Amabile CM, Vasudevan A. Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures. Pharmacotherapy. 2013;33(2):187-94.10.1002/phar.118523386597Search in Google Scholar

Articles recommandés par Trend MD

Planifiez votre conférence à distance avec Sciendo